NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 56 filers reported holding NUVALENT INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $98,108,346 | +9.8% | 2,134,182 | +0.7% | 0.00% | 0.0% |
| Q2 2023 | $89,335,458 | +65.4% | 2,118,460 | +2.3% | 0.00% | +100.0% |
| Q1 2023 | $54,012,718 | -9.9% | 2,070,246 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $59,926,531 | +114.0% | 2,012,308 | +39.7% | 0.00% | +100.0% |
| Q3 2022 | $28,007,000 | +63.9% | 1,440,693 | +14.3% | 0.00% | – |
| Q2 2022 | $17,088,000 | -24.9% | 1,260,165 | -23.0% | 0.00% | -100.0% |
| Q1 2022 | $22,745,000 | +57.3% | 1,637,507 | +115.6% | 0.00% | – |
| Q4 2021 | $14,464,000 | -14.4% | 759,672 | +1.4% | 0.00% | – |
| Q3 2021 | $16,890,000 | – | 748,980 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $918,987,373 | 20.25% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $164,446,964 | 18.39% |
| Fairmount Funds Management LLC | 2,451,819 | $112,710,119 | 13.56% |
| Paradigm Biocapital Advisors LP | 1,638,147 | $75,305,618 | 5.11% |
| COMMODORE CAPITAL LP | 828,778 | $38,098,925 | 4.45% |
| Perceptive Advisors | 2,463,451 | $113,244,842 | 3.78% |
| Boxer Capital, LLC | 1,210,192 | $55,632,526 | 2.96% |
| Tri Locum Partners LP | 113,528 | $5,218,882 | 1.67% |
| Ikarian Capital, LLC | 278,034 | $12,781,224 | 1.54% |
| Ikarian Capital, LLC | 2,395 | $11,009,815 | 1.32% |